TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Altimmune ( (ALT) ) just unveiled an announcement.
Altimmune, Inc. announced a leadership transition as Dr. Scott Harris, the former Chief Medical Officer, will retire on February 28, 2026. Christophe Arbet-Engels has been appointed as the new Chief Medical Officer, effective October 1, 2025. Dr. Harris will remain with the company as a Senior Strategic Advisor until his retirement, assisting in the transition of duties and continuing to receive his salary, benefits, and other compensations during this period.
The most recent analyst rating on (ALT) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Altimmune stock, see the ALT Stock Forecast page.
Spark’s Take on ALT Stock
According to Spark, TipRanks’ AI Analyst, ALT is a Neutral.
Altimmune’s overall stock score is driven by its financial challenges and valuation concerns, which are partially offset by positive developments in clinical trials and a strong cash position. The technical analysis provides mixed signals, contributing to a moderate overall score.
To see Spark’s full report on ALT stock, click here.
More about Altimmune
Average Trading Volume: 3,049,754
Technical Sentiment Signal: Sell
Current Market Cap: $341.6M
Find detailed analytics on ALT stock on TipRanks’ Stock Analysis page.